他汀类药物在蒽环类致心脏毒性中的保护作用机制研究进展  

Research progress on the protective mechanism of statins in anthracycline-induced cardiotoxicity

作　　者：王碗(综述) 王丽红(审校)[1] Wang Wan;Wang Lihong(Department of Hematology, Affiliated Hospital of Chengde Medical College, Hebei Province,Chengde 067000, China)

机构地区：[1]承德医学院附属医院血液内科,河北省承德067000

出　　处：《疑难病杂志》2022年第7期754-758,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：河北省自然科学基金资助项目(H2013406112)。

摘　　要：蒽环类药物是一种治疗血液肿瘤及各种实体肿瘤的强效化疗药之一,在靶向治疗的时代,蒽环类药物仍为抗癌基础用药,但严重的心脏毒副作用限制其临床应用,急需寻找有效预防心脏毒性的佐剂。研究发现,他汀类药物除降脂作用外,还可通过多种机制干扰蒽环类的心脏毒性作用,对心脏起到相应的保护作用,但具体机制尚未明确,文章针对他汀类药物在蒽环药物致心脏毒性的保护现状进行综述。Anthracyclines are one of the powerful chemotherapeutic drugs for the treatment of hematological tumors and various solid tumors.In the era of targeted therapy,anthracyclines are still the basic anticancer drugs,but serious cardiotoxicity and side effects limit their clinical use.It is urgent to find an adjuvant that can effectively prevent cardiotoxicity.Studies have found that in addition to lipid-lowering effects,statins can also interfere with the cardiotoxicity of anthracyclines through various mechanisms,and have a corresponding protective effect on the heart,but the specific mechanism is not yet clear.A review of the current status of protection against heart disease.

关 键 词：蒽环类药物 心脏毒性 他汀类药物 作用机制 

分 类 号：R541.9[医药卫生—心血管疾病] R979.14[医药卫生—内科学]